What Agomelatina treats: Main Uses and Benefits

Agomelatine is commonly used in adults for the acute treatment of Major Depressive Episodes and in the long-term for relapse prevention. The main approved use is the treatment of major depressive episodes in adults.

This medication is commonly used to help address symptom clusters that may become intense or disruptive, such as those associated with moderate to severe depression, including persistent low mood, deep sadness, and significant sleep disturbances.

“This supportive therapeutic benefit helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.”

The therapeutic approach is used in areas where short-term symptom management is appropriate and helps address symptom clusters related to core emotional symptoms, symptoms related to systemic imbalance (sleep disturbances), and loss of energy (anhedonia).

Quick Fact: Support for Sleep Disturbances

This medication is considered relevant in clinical settings marked by significant sleep disturbances that are a hallmark of depression. It is relevant for easing the symptoms related to systemic imbalance, which contributes to improved comfort during periods of heightened symptoms. It helps maintain a sense of stability when symptoms are more noticeable, and assists with managing symptoms related to loss of energy and anhedonia.

Eligibility for Agomelatine: Official Regulatory Status

Agomelatine is officially indicated for use in adults (18 to < 75 years) who do not have specific contraindications. Eligibility is strictly governed by a patient’s health status, age, and concomitant medications, as defined in regulatory documents like the Summary of Product Characteristics (SmPC).

Contraindicated Populations (Must Not Use):

Category	Exclusion Criteria
Hepatic Function	Hepatic impairment (e.g., active liver disease/cirrhosis) or transaminases (ALT/AST) exceeding 3 times the upper limit of normal (> 3 imes ULN).
Drug Interactions	Concomitant use of potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin).
Allergy	Hypersensitivity to the active substance or excipients.

Populations with Restricted or Conditional Use:

• Age Limits: Use is not recommended in patients under 18 years or those aged ge 75 years, as efficacy and safety have not been established. It is also not recommended for elderly patients with dementia.
• Psychiatric History: Patients with a history of mania, hypomania, or bipolar disorder require caution; treatment must be discontinued if manic symptoms develop.
• Pregnancy/Lactation: Use during pregnancy should be avoided as a precautionary measure due to limited data. It is not known if the drug is excreted into human milk, meaning a risk to the nursing infant cannot be excluded.

Interactions with other medicines and products

Agomelatina is principally metabolized by the Cytochrome P450 1A2 (CYP1A2) enzyme. Interactions are classified based on their effect on this metabolic pathway, resulting in specific regulatory constraints documented in prescribing information.

---

Formal Regulatory Restrictions

Category	Restrictions as Documented in Official Labeling
Contraindicated Combinations	Co-administration with potent CYP1A2 inhibitors is formally contraindicated. This includes specific medicines such as the antidepressant Fluvoxamine and the antibiotic Ciprofloxacin.
Use with Caution	Caution is advised with moderate CYP1A2 inhibitors, including Oestrogens (such as combined oral contraceptives), as these substances may result in a several-fold increased systemic exposure to agomelatine.
Decreased Exposure Risk	Enzyme inducers, such as Rifampicin or heavy smoking (defined as ge15 cigarettes/day), may decrease the drug's bioavailability due to increased CYP1A2 activity.

---

Substance and Population-Specific Notes

The combination of Agomelatina and alcohol is formally not advised due to the potential for an increased risk of hepatic injury. Furthermore, Agomelatina is contraindicated in patients with hepatic impairment because existing liver impairment can lead to a marked increase in drug exposure, which magnifies the risk associated with all drug-drug interactions.

How Agomelatina Works: Mechanism of Action

Agomelatine's pharmacological activity is defined by a unique dual mechanism within the Central Nervous System ( CNS) physiology, influencing both biological timing and neurochemical signaling.

Modulating the Circadian Rhythm via MT1 and MT2 Receptors

This domain focuses on the drug's chronobiotic action through the agonism of Melatonin MT1 and MT2 receptors in the brain's master clock, the Suprachiasmatic Nucleus ( SCN). By mimicking the action of endogenous melatonin, this mechanism promotes the resynchronization and phase correction of the sleep-wake cycle and other physiological rhythms.

Enhancing Dopamine and Norepinephrine via 5-HT2C Antagonism

This domain involves the drug's action as an antagonist at the Serotonin 5- HT2C receptor. Blocking this receptor removes an inhibitory brake, leading to the functional disinhibition and enhanced release of Dopamine ( DA) and Norepinephrine ( NE) specifically within the frontal cortex, which modulates neurotransmitter signaling within this region. The mechanism differs from those that rely on blocking the reuptake of neurotransmitters into the presynaptic neuron.

The Coordinated Dual-Action Cascade

The overall physiological effect arises from the synergy between these two mechanisms, which operate simultaneously. The integration of circadian synchronization and selective monoaminergic modulation contributes to the modulation of both the timing and the neurochemical balance of CNS activity.

How to Use Agomelatine

Agomelatine is administered exclusively via the oral route as a film-coated tablet. The official usage pattern establishes a precise daily schedule where the dose is taken once daily in the evening at bedtime. The tablets must be swallowed whole with water and may be taken with or without food.

---

Standard Dosing and Procedural Requirements

The recommended starting dose for adults is 25 mg of agomelatine taken once daily. If no improvement in symptoms is noted after a minimum of two weeks of treatment at the starting dose, the dosage may be adjusted upward to the maximum recommended dose of 50 mg once daily.

Procedural constraints dictate that liver function tests must be performed before the start of treatment and before any dose increase to the 50 mg level. If a dose is missed, patients should resume the schedule by taking the next dose at the regular time and must not take a double dose to compensate.

---

Duration and Population Constraints

Treatment duration is typically maintained for a sufficient period, generally at least six months to ensure freedom from symptoms following recovery. A key aspect of its labeled use is that no gradual dose reduction (tapering) is usually required when treatment is stopped.

Usage rules also restrict administration in certain groups. The medicine is not recommended for use in patients aged 75 years and older or for individuals under 18 years of age. Furthermore, it is contraindicated in patients with pre-existing hepatic impairment.

Research Evidence / Overview of Studies for Agomelatina

Evidence for Use in Acute Major Depressive Episodes (MDE)

Research evidence for Agomelatina in major depressive episodes has primarily been explored through short-term, randomized controlled trials (RCTs). These studies were conducted during periods of increased symptom activity, and research examined how symptoms evolved in adult populations diagnosed with unipolar depression. The typical follow-up duration for these acute trials was generally 6 to 12 weeks. Integrated analyses of the data reported patterns of difference in symptom scores compared to placebo, though the results varied across individual studies. Some trials described patterns where the findings were mixed, which contributes to an overall assessment that the certainty of the evidence remains low to moderate. What remains uncertain is the consistency of these initial findings across the entire body of evidence, especially in comparison to results that were not published in peer-reviewed journals.

Research on Long-Term Use and Relapse Prevention

Research explored whether Agomelatina may prevent the recurrence of symptoms over a longer period. These investigations used specialized, long-term continuation trials, which often lasted up to 24 to 52 weeks. Studies monitored outcomes related to the recurrence of a major depressive episode after a patient’s symptoms had already stabilized. Studies monitored findings that described a pattern of longer time-to-recurrence of symptoms compared to placebo in patients who had initially responded to the medicine. The body of evidence is limited to a small number of dedicated long-term randomized trials, and the existing findings were mixed.

Evidence for Associated Symptoms

Beyond the core symptoms of MDE, studies also monitored outcomes related to systemic or functional imbalance that were included in the evaluation. Research has explored changes measured in significant sleep disturbances and symptoms like anhedonia (a decreased ability to feel pleasure). Studies observed how patient-reported outcomes describing perceived discomfort and specific parameters of sleep changed during the study intervals. Research highlights changes measured in these specific symptoms, with findings indicating patterns related to measured sleep outcomes in comparison to some other antidepressants. Evidence is limited, as the trials were not specifically designed or powered to measure these associated symptoms as primary outcomes.

Evidence in Specific Adult Populations

Agomelatina was evaluated in broad groups of adults (18 to 75 years of age) with major depressive episodes. Specific subgroup analyses within the main trials have explored how different age groups, including older adults, were observed. While the results apply only to the populations studied, follow-up durations were limited across many subgroups. Research does not determine whether an individual within a subgroup will respond similarly. Subgroup findings are uncertain due to the modest sample sizes used in these analyses.

What Remains Uncertain About the Research Evidence

The broader evidence landscape contributes to understanding symptom patterns, but it also highlights key areas where more research is needed. Comparative evidence directly against a wide range of standard antidepressants is lacking in high-quality randomized trials. As noted in regulatory reviews, the magnitude of measured change in meta-analyses was often described as small, and evidence quality varies across studies. Long-term effects and the consistency of findings across all patient groups are not fully established, and more data are still emerging to address these gaps. Studies help show what has been observed so far, but research provides context and describes group patterns, not personal outcomes.

Key Studies & References Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials

Common questions about Agomelatina (FAQ)

Q: Can I drink alcohol while taking Agomelatine?

Co-administration with alcohol is not advised in the official product information. This recommendation is based on the potential for an increased risk of liver injury when alcohol is combined with this medicine. It is important to discuss alcohol consumption with a healthcare provider.

Q: What are the severe warnings or most serious side effects?

The most serious safety consideration documented in regulatory information is the risk of hepatotoxicity, or liver injury. This can include severe conditions like hepatitis and liver failure, which have been reported, particularly during the first few months of treatment. Official guidance indicates that patients should seek immediate medical attention if they notice signs of liver problems.

Q: When is the best time of day to take the tablet?

Official information states that this medicine should be taken once daily in the evening at bedtime. This specific timing is related to its mechanism of action, which involves influencing the body's natural sleep-wake cycle.

Q: What happens if I stop taking Agomelatine suddenly?

Studies and official information indicate that when treatment is stopped, no gradual dose reduction (tapering) is usually required. Clinical trials have not typically associated the sudden discontinuation of this medicine with withdrawal symptoms.

Q: How long until Agomelatine starts to work?

The official prescribing information suggests that if no improvement in symptoms is observed after a period of two weeks on the starting dose, a healthcare provider may consider increasing the dose. This timeframe is noted as a procedural checkpoint for healthcare providers when assessing whether a dose adjustment may be necessary.

Q: What happens if Agomelatine is crushed or chewed?

The official method of administration states that the film-coated tablets must be swallowed whole with water. The tablets must be swallowed whole to ensure the medicine is absorbed correctly.

Q: Can I drive or operate machinery while on this medication?

Since common side effects of this medicine include dizziness and somnolence (drowsiness), patients should exercise caution. Official product information suggests caution and notes that one should assess how the medicine affects them before engaging in activities that require attention.

Q: How do I dispose of expired Agomelatine?

Regulatory documents require that this medicine must not be disposed of via household waste or wastewater to protect the environment. Disposal should follow local requirements for unused or expired medicinal products, such as taking them to a pharmacy or using a dedicated medical waste service.

Q: What are the common clinical signs of liver problems I should watch for?

Regulatory documents list symptoms of potential liver injury for which patients should be vigilant. These symptoms include yellowing of the skin or eyes (jaundice), dark-colored urine, light-colored stools, pain in the upper right side of the abdomen, or new and sustained unexplained fatigue.

Q: Is Agomelatine addictive?

Information derived from clinical literature indicates that this medicine is not considered to be addictive. The conclusion is supported by the medicine not being typically associated with withdrawal symptoms upon discontinuation.

How to Store and Dispose of Agomelatine

Official regulatory documents define specific conditions for storing and discarding Agomelatine to ensure product integrity and safety.

Storage Requirements

Agomelatine tablets must be stored in the original container (blister pack) and should be kept below 25°C (but not exceeding 30 C). This requirement helps maintain the labeled three-year shelf life. For safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Agomelatine and any related waste material must be handled according to official environmental regulations. It is strictly required that this medicine not be disposed of via wastewater or household waste. Disposal should instead follow local requirements for unused medicinal products.